Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).

Launched by UNIVERSITY OF SASKATCHEWAN · Mar 6, 2021

Keywords

ClinConnect Summary

The BEEFBURGER Trial is a study looking at whether patients who have undergone coronary artery bypass graft (CABG) surgery still need to take beta-blockers, a type of medication that can help with heart issues. While beta-blockers are known to be very helpful for patients with weakened heart function or those at risk for certain heart problems, it’s not clear if they are still beneficial for patients without these risks after CABG surgery. This trial aims to gather more information about the long-term use of beta-blockers in these patients.

To participate in this trial, you need to be at least 18 years old and have had isolated CABG surgery. Additionally, you should still be taking beta-blockers at a follow-up appointment about 6 to 8 weeks after your surgery, and your heart function should be stable (with a certain level of heart strength measured recently). Participants can expect regular follow-up visits to track their health and how they respond to stopping or continuing beta-blocker therapy. The study is currently recruiting participants of all genders aged 65 and older. If you have any questions about your eligibility or the trial itself, it's a good idea to talk to your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years treated with index isolated CABG
• • Able to consent to study
• • On beta blocker therapy at the 6-8week visit
• • LV systolic function (≥45% assessed within 6months of CABG date)
• Exclusion Criteria:
• • Prior heart failure with reduced ejection fraction (LVEF \<45%)
• • Pre- or peri-operative atrial fibrillation or flutter
• • Peri-CABG stroke
• • Unable to follow-up